Journal List > Clin Exp Otorhinolaryngol > v.14(2) > 1157850

TOOLS
Kim, Lee, Kim, and Hwang: The Efficacy of Hypotensive Agents on Intraoperative Bleeding and Recovery Following General Anesthesia for Nasal Surgery: A Network Meta-Analysis
Original Article

Clin Exp Otorhinolaryngol 2021;14(2):200-209.

Published online: 28 August 2020

DOI: https://doi.org/10.21053/ceo.2020.00584

The Efficacy of Hypotensive Agents on Intraoperative Bleeding and Recovery Following General Anesthesia for Nasal Surgery: A Network Meta-Analysis

Do Hyun Kim1, Junuk Lee1, Sung Won Kim1, Se Hwan Hwang2

1Department of Otolaryngology-Head and Neck Surgery, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

2Department of Otolaryngology-Head and Neck Surgery, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

Corresponding author: Se Hwan Hwang Department of Otolaryngology-Head and Neck Surgery, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 327 Sosa-ro, Wonmi-gu, Bucheon 14647, Korea Tel: +82-32-340-7044, Fax: +82-32-340-2674 E-mail: yellobird@catholic.ac.kr

Received 9 April 2020       Revised 27 May 2020       Accepted 27 May 2020

Copyright © 2021 by Korean Society of Otorhinolaryngology-Head and Neck Surgery

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objectives

A systematic review of the literature was conducted to evaluate hypotensive agents in terms of their adverse effects and associations with perioperative morbidity in patients undergoing nasal surgery.

Methods

Two authors independently searched databases (Medline, Scopus, and Cochrane databases) up to February 2020 for randomized controlled trials comparing the perioperative administration of a hypotensive agent with a placebo or other agent. The outcomes of interest for this analysis were intraoperative morbidity, operative time, intraoperative bleeding, hypotension, postoperative nausea/vomiting, and postoperative pain. Both a standard pairwise meta-analysis and network meta-analysis were conducted.

Results

Our analysis was based on 37 trials. Treatment networks consisting of six interventions (placebo, clonidine, dexmedetomidine, beta-blockers, opioids, and nitroglycerine) were defined for the network meta-analysis. Dexmedetomidine resulted in the greatest differences in intraoperative bleeding (−0.971; 95% confidence interval [CI], −1.161 to −0.781), intraoperative fentanyl administration (−3.683; 95% CI, −4.848 to −2.518), and postoperative pain (−2.065; 95% CI, −3.170 to −0.960) compared with placebo. The greatest difference in operative time compared with placebo was achieved with clonidine (−0.699; 95% CI, −0.977 to −0.421). All other agents also had beneficial effects on the measured outcomes. Dexmedetomidine was less likely than other agents to cause adverse effects.

Conclusion

This study demonstrated the superiority of the systemic use of dexmedetomidine as a perioperative hypotensive agent compared with the other five tested agents. However, the other agents were also superior to placebo in improving operative time, intraoperative bleeding, and postoperative pain.

Keywords: Antihypertensive Agents, Nasal Surgical Procedures, Morbidity, Controlled Hypotension

INTRODUCTION

Regardless of whether nasal surgery, such as septoplasty and endoscopic sinus surgery, is performed under local or general anesthesia [1], intraoperative bleeding can cause difficulties with airway management [2]. To prevent airway problems during nasal surgery, general anesthesia is preferred [3], although it can lower capillary resistance and thereby increase the bleeding risk [4]. In addition, the medications used for general anesthesia can change vascular elasticity and cardiovascular reflexes, such as peripheral vasodilation, while decreasing the activity of the sympathetic nervous system. Previous in vivo studies showed a decrease in vascular resistance in patients under general anesthetics [5].
Bleeding during otorhinolaryngologic surgery reduces intraoperative visibility, which greatly hinders the procedure. Several agents, such as beta-blockers, alpha-blockers, and opioids, can be used to maintain a low intraoperative blood pressure, thereby reducing intraoperative blood loss and improving visualization of the surgical field [6,7]. Traditional meta-analyses of the effects of individual agents on blood loss have been conducted, but they were inherently limited to direct pairwise comparisons between a single treatment and a single alternative, whereas multiple treatment options and the ranking thereof were methodologically not possible. In contrast, a network meta-analysis (NMA) can be used to compare multiple treatment options simultaneously, as it combines all direct and indirect evidence from randomized controlled trials (RCTs). Moreover, an NMA provides a ranking of the assessed treatment options, thus allowing clinicians to choose the most effective treatment [8]. In this review, we present the results of our NMA of the efficacy of six different hypotensive agents used during nasal surgery. The findings can simplify evidence-based clinical decision-making in the management of patients undergoing nasal surgery.

MATERIALS AND METHODS

Search strategy and selection of studies

The search strategy was designed and reviewed by a clinical librarian, who has been an information specialist for more than 10 years. And the searching of the database such as Medline, Scopus, the Cochrane Controlled Register of Trials, and google scholar were performed in February 2020. We also tracked the reference lists of included studies and checked the existing systematic reviews to find relevant studies. Parts of the strategies are listed in Supplementary Tables 1-3, and diagram of the study selection process was presented in Fig. 1. The duplicated and apparently irrelevant studies were excluded through screening titles and abstracts by two reviewers (DHK, SHH) independently, and full texts of potentially eligible articles were assessed for inclusion independently by two reviewers once more. Any discrepancy in the selection of literature was resolved by consensus or the third author.
All relevant RCTs were included for minimizing the influence of the population characteristics such as distribution of age, sex, or severity of nasal disease status in the individual studies. All enrolled studies evaluated the hypotensive agents in terms of their adverse effects and induction of perioperative morbidity in patients undergoing nasal surgery. In terms of participants, only adult-patients (more than 18 years old) undergoing nasal surgery including mainly endoscopic sinus surgery for chronic rhinosinusitis as well as septoplasty and rhinoplasty were included, and the physical condition of enrolled patients was in American Society of Anesthesiologists class I (healthy) or II (mild systemic disease). Patients with cardiovascular diseases, patients receiving cardiovascular active drugs, and patients receiving drugs influencing blood coagulation were excluded. Missing or incomplete data in the included studies were directly obtained from the authors. This NMA is reported based on the Preferred Reporting Items for Systematic Reviews and Meta-analyses for NMA.

Data extraction and risk of bias assessment

Data from the included studies were extracted using standardized forms and independently examined by the two authors. The evaluated outcomes consisted of operative time [1,3,6,9-35], mean intraoperative bleeding [1,6,9,12-15,17,22,25-27,33,34, 36,37], dose of intraoperative fentanyl administered [1,6,13,15, 19,22,30,32,38], postoperative pain [3,7,10,11,22,33,36,39], the occurrence of postoperative nausea and vomiting (incidence or percentage of patients) [3,7,10,11,13,19,22,27,29,31,33,39, 40], and intraoperative hypotension [3,11,13,22,27,32,35,36, 39,41]. The outcomes were compared with respect to the other treatment strategies and the control groups. Data were extracted from the included studies regarding patient number, grading scale, amount of analgesics, incidence of adverse effects, and P-values for comparisons of the various agents and respective patient groups. The risk of bias for each study was evaluated using the Cochrane risk of bias tool.

Statistical analysis

The meta-analysis was performed using R 3.5.0 netmeta package (R Foundation for Statistical Computing, Vienna, Austria). A random-effects NMA within a frequentist framework [42] was conducted to achieve combined results in the form of standardized mean differences and 95% confidence intervals (95% CIs) for use across all studies to assess operative time, mean intraoperative bleeding, intraoperative fentanyl dose administered, and postoperative pain. In all other cases, the outcomes of the incidence analysis were assessed using odds ratios. To rank treatment options graphically, the surface under the cumulative ranking curve (SUCRA) and mean ranks were adopted. SUCRA represents the probability of a treatment ranking best [44]. In this study, SUCRA ranged from 0 to 1, with 1 indicating that the treatment option was statistically best and 0 the worst. Direct and indirect comparisons were adequately homogeneous. A loop-specific approach was used to distinguish heterogeneity in all triangular or quadratic loops in the NMA model [45]. The discrepancy between direct and indirect evidence with the 95% CI was used to distinguish heterogeneity in all loops. Heterogeneity was defined as the difference between direct and indirect evidence with a 95% CI excluding 0. The node-splitting model was used to distinguish heterogeneity between the direct and indirect evidence [46]. In addition, we made comparison-adjusted funnel plots to assess potential publication bias [47].

RESULTS

The literature review yielded 37 studies containing 1945 participants. Table 1 shows the results of the bias assessment and the study characteristics. Clonidine had the greatest effect on operative time compared with placebo (−0.699; 95% CI, −0.977 to −0.421), followed by dexmedetomidine (−0.466; 95% CI, −0.705 to −0.226), opioids (−0.418; 95% CI, −0.728 to −0.108), nitroglycerin (−0.260; 95% CI, −0.651 to 0.132), and beta-blockers (−0.253; 95% CI, −0.554 to 0.048) (Fig. 2A). In terms of intraoperative fentanyl administration, dexmedetomidine had the greatest effect compared with placebo (−3.683; 95% CI, −4.848 to −2.518), followed by nitroglycerin (−1.491; 95% CI, −3.224 to 0.242), beta-blockers (−1.039; 95% CI, −2.739 to 0.661), and clonidine (−0.417; 95% CI, −2.022 to 1.188) (Fig. 2B). The greatest effect on intraoperative bleeding compared with placebo was achieved with dexmedetomidine (−0.971; 95% CI, −1.161 to −0.781), followed by nitroglycerin (−0.945; 95% CI, −1.420 to −0.470), opioids (−0.691; 95% CI, −0.968 to −0.414), clonidine (−0.571; 95% CI, −0.768 to −0.374), and beta-blockers (−0.437; 95% CI, −0.650 to −0.225) (Fig. 2C). The greatest effect on postoperative pain compared with placebo was observed for dexmedetomidine (−2.065; 95% CI, −3.170 to −0.960), followed by beta-blockers (−1.414; 95% CI, −3.059 to 0.232), clonidine (−1.151; 95% CI, −2.519 to 0.218), and opioids (−0.764; 95% CI, −2.054 to 0.526) (Fig. 2D). Intraoperative and postoperative morbidities were in part attributed to the adverse effects of the hypotensive agents evaluated. The binary outcomes of hypotension and nausea/vomiting showed no significant differences in intraoperative or postoperative morbidities between the treated and control groups (Fig. 2E and F).
An evaluation of whether the direct and indirect comparisons were sufficiently similar in the NMA showed no global inconsistencies regarding intraoperative bleeding (P=0.255), hypotension (P=0.222), nausea and vomiting (P=0.080), pain (P=0.617), intraoperative fentanyl administration (P=0.151), or operative time (P=0.674). Additionally, there were no local inconsistencies among outcomes, except for direct (−0.217) and indirect (−0.710) comparisons of operative time for clonidine. However, this discrepancy only involved the effect size, which may not be meaningful for assessing the effectiveness of a hypotensive agent (Supplementary Tables 4-9).

Results of the ranking hierarchy

Table 2 shows that dexmedetomidine was superior in terms of pain, intraoperative bleeding, and intraoperative fentanyl administration and ranked second in terms of operative time. There were no statistically significant differences among the tested agents with respect to intraoperative hypotension and postoperative nausea, although dexmedetomidine ranked first and second in postoperative nausea and intraoperative hypotension, respectively. Clonidine ranked first in terms of operative time. Nitroglycerin ranked second in terms of intraoperative bleeding and intraoperative fentanyl administration, but it was not evaluated for hypotension or postoperative pain.

Detection of publication bias

In all six comparison-adjusted funnel plots (Fig. 3), the scatter plots with the same symbols were visually symmetrical, meaning that publication bias was relatively low for operative time, intraoperative fentanyl administration, intraoperative bleeding, postoperative pain, hypotension, and nausea and vomiting. A linear regression test of funnel plot asymmetry also showed no significant publication bias (P>0.05).

DISCUSSION

Previous meta-analyses have documented the efficacy of several hypotensive agents in decreasing intraoperative bleeding and improving the surgical view during nasal surgery, especially when performed endoscopically [48-52]. However, the limitations of these studies hindered their clinical relevance, as they consisted of conventional pairwise meta-analyses, which can compare only two treatments, but cannot assess multiple treatments or provide a ranking of their effectiveness [42]. This makes it difficult for clinicians to select the optimal treatment among several treatments demonstrated to be effective in previous meta-analyses.
NMA is a novel analytic approach that enables simultaneous comparisons of multiple interventions. It also allows quantitative comparisons of treatments that previously had not been compared directly [53], by using direct and indirect data and combinations of evidence from different dimensions [8]. This study utilized NMA to resolve the limitations of previous studies of nasal surgery that examined single, rather than multiple, treatment options. Specifically, we conducted a systematic review using an NMA to rank the effects of six agents used to induce intraoperative hypotension based on intraoperative and postoperative morbidity endpoints.
Although they have no direct sympathomimetic effects and do not influence vasodilation, opioids, in particular remifentanil, reduce surgical blood loss by effectively lowering heart rate, cardiac output, and blood pressure without the need for other hypotensive agents [35]. Based on recent reports, we defined six intervention groups—placebo, clonidine, dexmedetomidine, beta-blockers, nitroglycerine, and opioids—and constructed treatment networks for the NMA. All of the studied agents showed beneficial effects on reducing intraoperative bleeding, but only dexmedetomidine had positive effects on all of the other examined outcomes (operative time, intraoperative fentanyl administration, and postoperative pain) and ranked highest compared with placebo for all outcomes except operative time. Clonidine had the greatest effect on reducing operative time, but it did not significantly reduce either intraoperative fentanyl administration or postoperative pain. Although none of the hypotensive agents evaluated were associated with significant adverse effects, such as severe hypotension or nausea/vomiting, the best results were obtained with dexmedetomidine.
Dexmedetomidine is a highly selective alpha 2-adrenoceptor agonist that reduces intraoperative bleeding by lowering blood pressure, thereby achieving hemodynamic stability [50]. Additionally, dexmedetomidine exerts both sedative and analgesic effects without suppressing the respiratory response [2]. The control of intraoperative bleeding contributes to successful surgery by improving visualization of the operating field. When intraoperative bleeding occurs, surgeons must pause the procedure for bleeding control to restore the surgical view, increasing the operative time [7,31]. This explains the relationship between intraoperative bleeding and operative time in our study and the ability of dexmedetomidine to reduce both.
The stress associated with nasal surgery stimulates the sympathetic nervous system [54]. Opioids have been used to prevent sympathetic stimulation and to provide hemodynamic stability during surgery [55]. However, some studies have shown that opioids also reduce intraoperative bleeding and provide a clear surgical view, while others have reported side effects such as nausea/vomiting, respiratory depression, pruritus, sinus bradycardia, and hypotension [7]. Dexmedetomidine alleviates stress-induced responses and provides relatively stable hemodynamics during surgery [7,54]. Our study found that fentanyl administration was significantly lower in the dexmedetomidine group than in the placebo group. These results demonstrate the efficient sympatholytic and analgesic-sparing properties of dexmedetomidine [55,56].
Postoperative pain related to nasal surgery significantly affects patient recovery and requires early and often aggressive management [57]. Surgical trauma itself stimulates nociception and postoperative pain, but it also induces the release of inflammatory mediators from immune cells and non-neuronal cells, resulting in peripheral sensitization, while the partial peripheral nociceptive stimulus may directly cause central sensitization [57]. Dexmedetomidine inhibits the increased release of inflammatory cytokines and exhibits analgesic effects by acting on alpha-2 receptors within the locus coeruleus and spinal cord [7]. These actions inhibit both peripheral and central sensitization, thereby alleviating postoperative pain. In this study, dexmedetomidine significantly reduced postoperative pain but opioids did not, perhaps because hyperalgesia is one of the side effects of opioids [32]. Thus, the overall results showed that dexmedetomidine provides sufficient adjuvant efficiency for patients under general anesthesia.
Nausea/vomiting and hypotension are common adverse effects of hypotensive drugs. In this study, there was no statistically significant difference in the incidence of perioperative adverse effects between the treatment and control groups. Previous studies have shown that a slow loading dose of dexmedetomidine (1 μg/kg over 10 minutes and continuous infusion at 0.3–0.7 μg/kg/hr) can reduce the development of adverse effects [7,58]. The safe administration protocols adopted by the studies included in our NMA explain the absence of a significant difference in the frequency of adverse effects.
Our results suggest that dexmedetomidine use in patients undergoing nasal surgery can improve surgical outcomes without serious side effects. Compared with the other hypotensive agents evaluated in our NMA, dexmedetomidine exhibited similar or superior effects in controlling postoperative pain and blood pressure.
However, it should be noted that some of the included studies enrolled small number of patients or performed comparisons based only on indirect evidence. We were also unable to control for the drug administration protocol. In addition, although obtaining a larger sample size via an NMA could enhance reliability and might be clinically useful [47], NMAs have limitations as a statistical method that only assesses computable and numerical information. In particular, unpredictable and difficult-to-quantify variables such as surgeon-related factors or the system of each hospital can affect outcomes [59]. Therefore, the findings of this study that dexmedetomidine showed good results for intraoperative bleeding and that clonidine showed favorable results for operative time might have been affected by unpredictable variables. Thus, care should be taken when interpreting these clinical results.
The results of our NMA showed that the systemic use of dexmedetomidine can decrease surgery-related pain without adverse effects, such as nausea/vomiting and significant hypotension, and thus may decrease the need for postoperative analgesics. However, prior to surgery, clinicians must inform patients about the intraoperative use of hypotensive agents.

HIGHLIGHTS

▪ Bleeding during otorhinolaryngologic surgery reduces intraoperative visibility, which greatly hinders the procedure.
▪ Dexmedetomidine showed promise as a perioperative hypotensive agent.
▪ Clonidine, dexmedetomidine, beta-blockers, opioids, and nitroglycerine improved operative time, intraoperative bleeding, and postoperative pain.

Notes

No potential conflict of interest relevant to this article was reported.

ACKNOWLEDGMENTS

The search strategy was constructed by the clinical librarian at Bucheon St. Mary’s Hospital.
This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2018R1D1A1B07045421), the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Ministry of Science & ICT (2018M3A9E8020856, 2019M3A9H2032424, 2019M3E5D5064110), and the Korea Health Industry Development Institute funded by the Ministry of Health and Welfare (HI14C3228), and the Institute of Clinical Medicine Research of Bucheon St. Mary’s Hospital, Research Fund (2017, 2018). This research was also supported by a grant from the E.N.T. Fund of the Catholic University of Korea (program years 2017-2018). The sponsors had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Notes

AUTHOR CONTRIBUTIONS

Conceptualization: DHK, SHH. Data curation: DHK, JL. Formal analysis: SWK, SHH. Funding acquisition: DHK, SWK, SHH. Methodology: SHH. Project administration: DHK, SHH. Visualization: JL, SWK, SHH. Writing–original draft: DHK, JL, SWK, SHH. Writing–review & editing: DHK, JL, SWK, SHH.

Supplementary Materials

Supplementary Table 1.
Search strategy of PubMed
ceo-2020-00584-suppl1.pdf
Supplementary Table 2.
Search strategy of Embase
ceo-2020-00584-suppl2.pdf
Supplementary Table 3.
Search strategy of the Cochrane database
ceo-2020-00584-suppl3.pdf
Supplementary Table 4.
Standardized mean differences with 95% confidence intervals from the network meta-analysis of operative time
ceo-2020-00584-suppl4.pdf
Supplementary Table 5.
Standardized mean differences with 95% confidence intervals from the network meta-analysis of intraoperative fentanyl administration
ceo-2020-00584-suppl5.pdf
Supplementary Table 6.
Standardized mean differences with 95% confidence intervals from the network meta-analysis of intraoperative bleeding
ceo-2020-00584-suppl6.pdf
Supplementary Table 7.
Standardized mean differences with 95% confidence intervals from the network meta-analysis of postoperative pain
ceo-2020-00584-suppl7.pdf
Supplementary Table 8.
Standardized mean differences with 95% confidence intervals from the network meta-analysis of hypotension
ceo-2020-00584-suppl8.pdf
Supplementary Table 9.
Standardized mean differences with 95% confidence intervals from the network meta-analysis of nausea and vomiting
ceo-2020-00584-suppl9.pdf

REFERENCES

1. Shams T, El Bahnasawe NS, Abu-Samra M, El-Masry R. Induced hypotension for functional endoscopic sinus surgery: a comparative study of dexmedetomidine versus esmolol. Saudi J Anaesth. 2013; Apr. 7(2):175–80.
crossref
2. Lee K, Yoo BH, Yon JH, Kim KM, Kim MC, Lee WY, et al. General anesthesia versus monitored anesthetic care with dexmedetomidine for closed reduction of nasal bone fracture. Korean J Anesthesiol. 2013; Sep. 65(3):209–14.
crossref
3. Kim H, Ha SH, Kim CH, Lee SH, Choi SH. Efficacy of intraoperative dexmedetomidine infusion on visualization of the surgical field in endoscopic sinus surgery. Korean J Anesthesiol. 2015; Oct. 68(5):449–54.
crossref
4. Bunker JP. Anesthetic effects on surgical blood loss. Ann N Y Acad Sci. 1964; Jul. 115:418–21.
crossref
5. Akata T. General anesthetics and vascular smooth muscle: direct actions of general anesthetics on cellular mechanisms regulating vascular tone. Anesthesiology. 2007; Feb. 106(2):365–91.
6. Ayoglu H, Yapakci O, Ugur MB, Uzun L, Altunkaya H, Ozer Y, et al. Effectiveness of dexmedetomidine in reducing bleeding during septoplasty and tympanoplasty operations. J Clin Anesth. 2008; Sep. 20(6):437–41.
crossref
7. Gupta P, Choudhary R, Ojha D, Jethava D. Dexmedetomidine as an adjuvant for hypotensive anaesthesia during functional endoscopic sinus surgery (FESS). IOSR Dental Med Sci. 2016; Aug. 15(8):143–6.
crossref
8. Rouse B, Chaimani A, Li T. Network meta-analysis: an introduction for clinicians. Intern Emerg Med. 2017; Feb. 12(1):103–11.
crossref
9. Cardesin A, Pontes C, Rosell R, Escamilla Y, Marco J, Escobar MJ, et al. A randomised double blind clinical trial to compare surgical field bleeding during endoscopic sinus surgery with clonidine-based or remifentanil-based hypotensive anaesthesia. Rhinology. 2015; Jun. 53(2):107–15.
crossref
10. Bairy L, Vanderstichelen M, Jamart J, Collard E. Clonidine or remifentanil for adequate surgical conditions in patients undergoing endoscopic sinus surgery: a randomized study. PeerJ. 2017; May. 5:e3370.
crossref
11. Erdivanli B, Erdivanli OC, Sen A, Ozdemir A, Tugcugil E, Dursun E. Comparison of metoprolol and tramadol with remifentanil in endoscopic sinus surgery: a randomised controlled trial. Turk J Anaesthesiol Reanim. 2018; Dec. 46(6):424–33.
crossref
12. Jangra K, Malhotra SK, Gupta A, Arora S. Comparison of quality of the surgical field after controlled hypotension using esmolol and magnesium sulfate during endoscopic sinus surgery. J Anaesthesiol Clin Pharmacol. 2016; Jul-Sep. 32(3):325–8.
crossref
13. Das A, Chhaule S, Bhattacharya S, Basunia SR, Mitra T, Halder PS, et al. Controlled hypotension in day care functional endoscopic sinus surgery: a comparison between esmolol and dexmedetomidine: a prospective, double-blind, and randomized study. Saudi J Anaesth. 2016; Jul-Sep. 10(3):276–82.
crossref
14. Tugrul S, Dogan R, Senturk E, Kocak I, Sezen S, Bakan M, et al. Effect of the premedication with oral clonidine on surgical comfort in patients undergoing fess due to advanced nasal polyposis: a randomized double blind clinical trial. Am J Otolaryngol. 2016; Nov-Dec. 37(6):538–43.
crossref
15. Jabalameli M, Hashemi M, Soltani H, Hashemi J. Oral clonidine premedication decreases intraoperative bleeding in patients undergoing endoscopic sinus surgery. J Res Med Sci. 2005; Jan. 1:25–30.
16. Wawrzyniak K, Kusza K, Cywinski JB, Burduk PK, Kazmierczak W. Premedication with clonidine before TIVA optimizes surgical field visualization and shortens duration of endoscopic sinus surgery: results of a clinical trial. Rhinology. 2013; Sep. 51(3):259–64.
17. Mohseni M, Ebneshahidi A. The effect of oral clonidine premedication on blood loss and the quality of the surgical field during endoscopic sinus surgery: a placebo-controlled clinical trial. J Anesth. 2011; Aug. 25(4):614–7.
crossref
18. Alkan A, Honca M, Alkan A, Gulec H, Horasanli E. The efficacy of esmolol, remifentanil and nitroglycerin in controlled hypotension for functional endoscopic sinus surgery. Braz J Otorhinolaryngol. 2019; Oct. S1808-8694(18):30493–2.
crossref
19. Bajwa SJ, Kaur J, Kulshrestha A, Haldar R, Sethi R, Singh A. Nitroglycerine, esmolol and dexmedetomidine for induced hypotension during functional endoscopic sinus surgery: a comparative evaluation. J Anaesthesiol Clin Pharmacol. 2016; Apr-Jun. 32(2):192–7.
crossref
20. El-Shmaa NS, Ezz HA, Younes A. The efficacy of Labetalol versus nitroglycerin for induction of controlled hypotension during sinus endoscopic surgery: a prospective, double-blind and randomized study. J Clin Anesth. 2017; Jun. 39:154–8.
crossref
21. Srivastava U, Dupargude AB, Kumar D, Joshi K, Gupta A. Controlled hypotension for functional endoscopic sinus surgery: comparison of esmolol and nitroglycerine. Indian J Otolaryngol Head Neck Surg. 2013; Aug. 65(Suppl 2):440–4.
crossref
22. Sajedi P, Rahimian A, Khalili G. Comparative evaluation between two methods of induced hypotension with infusion of remifentanil and labetalol during sinus endoscopy. J Res Pharm Pract. 2016; Oct-Dec. 5(4):264–71.
crossref
23. Cardesin A, Pontes C, Rosell R, Escamilla Y, Marco J, Escobar MJ, et al. Hypotensive anaesthesia and bleeding during endoscopic sinus surgery: an observational study. Eur Arch Otorhinolaryngol. 2014; Jun. 271(6):1505–11.
crossref
24. Wawrzyniak K, Burduk PK, Cywinski JB, Kusza K, Kazmierczak W. Improved quality of surgical field during endoscopic sinus surgery after clonidine premedication--a pilot study. Int Forum Allergy Rhinol. 2014; Jul. 4(7):542–7.
crossref
25. Nair S, Collins M, Hung P, Rees G, Close D, Wormald PJ. The effect of beta-blocker premedication on the surgical field during endoscopic sinus surgery. Laryngoscope. 2004; Jun. 114(6):1042–6.
26. Shen PH, Weitzel EK, Lai JT, Wormald PJ, Ho CS. Intravenous esmolol infusion improves surgical fields during sevoflurane-anesthetized endoscopic sinus surgery: a double-blind, randomized, placebo-controlled trial. Am J Rhinol Allergy. 2011; Nov-Dec. 25(6):e208–11.
crossref
27. Bayram A, Ulgey A, Gunes I, Ketenci I, Capar A, Esmaoglu A, et al. Comparison between magnesium sulfate and dexmedetomidine in controlled hypotension during functional endoscopic sinus surgery. Rev Bras Anestesiol. 2015; Jan-Feb. 65(1):61–7.
crossref
28. Kavalci G, Ethemoglu FB, Durukan P, Batuman A, Emre C. Comparison of the effects of dexmedetomidine and remiphentanyl on emergence agitation after sevoflurane anesthesia in adults undergoing septoplasty operation: a randomized double-blind trial. Eur Rev Med Pharmacol Sci. 2013; Nov. 17(22):3019–23.
29. Ozcan AA, Ozyurt Y, Saracoglu A, Erkal H, Suslu H, Arslan G, et al. Dexmedetomidine versus remifentanil for controlled hypotensive anesthesia in functional endoscopic sinus surgery. Turk J Anesth Reanim. 2012; Jul. 40(5):257–61.
30. Kaur H, Tiwari RL, Bhargava J, Kasliwal N. Effect of dexmedetomidine on consumption of anesthetic agents, duration of surgery, time to extubation and post-operative emergence during endoscopic nasal surgeries: a pilot study. Scholars J Appl Med Sci. 2016; Apr. 4(6E):2180–6.
crossref
31. Xu K, Pan Y, Zhu M. Effects of dexmedetomidine on the recovery profiles from general anesthesia in patients undergoing endoscopic sinus surgery. Int J Clin Exp Med. 2016; Sep. 9(5):8405–10.
32. Gupta K, Gupta PK, Bhatia KS, Rastogi B, Pandey MN, Agarwal S. Efficacy of dexmedetomidine as an anesthetic adjuvant for functional endoscopic sinus surgery under general anesthesia: a randomizedcontrolled study. Ain-Shams J Anaesthesiol. 2016; Sep. 9(2):207–11.
crossref
33. Kim SY, Kim JM, Lee JH, Song BM, Koo BN. Efficacy of intraoperative dexmedetomidine infusion on emergence agitation and quality of recovery after nasal surgery. Br J Anaesth. 2013; Aug. 111(2):222–8.
crossref
34. Karabayirli S, Ugur KS, Demircioglu RI, Muslu B, Usta B, Sert H, et al. Surgical conditions during FESS; comparison of dexmedetomidine and remifentanil. Eur Arch Otorhinolaryngol. 2017; Jan. 274(1):239–45.
crossref
35. Lee J, Kim Y, Park C, Jeon Y, Kim D, Joo J, et al. Comparison between dexmedetomidine and remifentanil for controlled hypotension and recovery in endoscopic sinus surgery. Ann Otol Rhinol Laryngol. 2013; Jul. 122(7):421–6.
crossref
36. Jiwanmall M, Joselyn AS, Kandasamy S. Intravenous clonidine as a part of balanced anaesthesia for controlled hypotension in functional endoscopic sinus surgery: a randomised controled trial. Indian J Anaesth. 2017; May. 61(5):418–23.
crossref
37. Kumari I, Sharma S, Surendran K, Naithani U, Saxena SS, Yadav R. Effect of dexmedetomidine on bleeding during endoscopic nasal surgery: a double blind, randomized, clinical study. Eur J Pharm Med Res. 2016; Mar. 3(12):290–4.
38. Praveen DV, Pushparani A, Anand K, Sundaraperumal B. Comparison of dexmedetomidine with nitroglycerinefor hypotensive anaesthesia in. Indian J Clin Anesth. 2016; May. 3(3):376–88.
39. Polat R, Peker K, Baran I, Bumin Aydın G, Topcu Guloksuz C, Donmez A. Comparison between dexmedetomidine and remifentanil infusion in emergence agitation during recovery after nasal surgery: A randomized double-blind trial. Anaesthesist. 2015; Oct. 64(10):740–6.
40. Aksu R, Akin A, Bicer C, Esmaoglu A, Tosun Z, Boyaci A. Comparison of the effects of dexmedetomidine versus fentanyl on airway reflexes and hemodynamic responses to tracheal extubation during rhinoplasty: A double-blind, randomized, controlled study. Curr Ther Res Clin Exp. 2009; Jun. 70(3):209–20.
crossref
41. Rahimzadeh P, Faiz SH, Alebouyeh MR. Effects of premedication with metoprolol on bleeding and induced hypotension in nasal surgery. Anesth Pain Med. 2012; Winter. 1(3):157–61.
crossref
42. Shim S, Yoon BH, Shin IS, Bae JM. Network meta-analysis: application and practice using Stata. Epidemiol Health. 2017; Oct. 39:e2017047.
crossref
43. Khurshid DH, Muneer DK, Sadiq Malla M. Effect of dexmedetomidine on emergence agitation after nasal surgeries. Med Sci Clin Res. 2015; 3(9):7527–31.
crossref
44. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011; Feb. 64(2):163–71.
crossref
45. Higgins JP, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods. 2012; Jun. 3(2):98–110.
crossref
46. van Valkenhoef G, Dias S, Ades AE, Welton NJ. Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis. Res Synth Methods. 2016; Mar. 7(1):80–93.
47. Flather MD, Farkouh ME, Pogue JM, Yusuf S. Strengths and limitations of meta-analysis: larger studies may be more reliable. Control Clin Trials. 1997; Dec. 18(6):568–79.
crossref
48. Lee HS, Yoon HY, Jin HJ, Hwang SH. Can dexmedetomidine influence recovery profiles from general anesthesia in nasal surgery. Otolaryngol Head Neck Surg. 2018; Jan. 158(1):43–53.
crossref
49. Quijada-Manuitt MA, Escamilla Y, Vallano A, Cardesin A, Bernal-Sprekelsen M, Pontes C. Use of α2-adrenergic agonists to improve surgical field visibility in endoscopy sinus surgery: a systematic review of randomized controlled trials. Clin Ther. 2018; Jan. 40(1):136–49. e19.
50. Snidvongs K, Tingthanathikul W, Aeumjaturapat S, Chusakul S. Dexmedetomidine improves the quality of the operative field for functional endoscopic sinus surgery: systematic review. J Laryngol Otol. 2015; Jul. 129 Suppl 3:S8–13.
crossref
51. Amorocho MC, Fat I. Anesthetic techniques in endoscopic sinus and skull base surgery. Otolaryngol Clin North Am. 2016; Jun. 49(3):531–47.
crossref
52. Baker AR, Baker AB. Anaesthesia for endoscopic sinus surgery. Acta Anaesthesiol Scand. 2010; Aug. 54(7):795–803.
crossref
53. Kanters S, Ford N, Druyts E, Thorlund K, Mills EJ, Bansback N. Use of network meta-analysis in clinical guidelines. Bull World Health Organ. 2016; Oct. 94(10):782–4.
crossref
54. Bhagat N, Yunus M, Karim HM, Hajong R, Bhattacharyya P, Singh M. Dexmedetomidine in attenuation of haemodynamic response and dose sparing effect on opioid and anaesthetic agents in patients undergoing laparoscopic cholecystectomy: a randomized study. J Clin Diagn Res. 2016; Nov. 10(11):UC01–5.
55. Manne GR, Upadhyay MR, Swadia V. Effects of low dose dexmedetomidine infusion on haemodynamic stress response, sedation and postoperative analgesia requirement in patients undergoing laparoscopic cholecystectomy. Indian J Anaesth. 2014; Nov-Dec. 58(6):726–31.
crossref
56. Khan ZP, Munday IT, Jones RM, Thornton C, Mant TG, Amin D. Effects of dexmedetomidine on isoflurane requirements in healthy volunteers. 1: Pharmacodynamic and pharmacokinetic interactions. Br J Anaesth. 1999; Sep. 83(3):372–80.
crossref
57. Tang C, Huang X, Kang F, Chai X, Wang S, Yin G, et al. Intranasal dexmedetomidine on stress hormones, inflammatory markers, and postoperative analgesia after functional endoscopic sinus surgery. Mediators Inflamm. 2015; 2015:939431.
crossref
58. Lee SK. Clinical use of dexmedetomidine in monitored anesthesia care. Korean J Anesthesiol. 2011; Dec. 61(6):451–2.
crossref
59. Bailar JC 3rd. The promise and problems of meta-analysis. N Engl J Med. 1997; Aug. 337(8):559–61.
crossref

Fig. 1.
Diagram of the study selection process.
ceo-2020-00584f1.tif
Fig. 2.
Evidence structure of eligible comparisons (left) and forest plots (right) for the network meta-analysis. (A) Operative time, (B) fentanyl administration, (C) intraoperative bleeding, (D) postoperative pain, (E) hypotension, and (F) nausea and vomiting. Lines indicate direct comparisons in the eligible randomized controlled studies (RCTs). The width of the lines represents the number of RCTs for each pairwise comparison. The standardized mean differences and relative risks of intraoperative and postoperative events are shown. SMD, standardized mean difference; CI, confidence interval; OR, odds ratio.
ceo-2020-00584f2.tif
Fig. 3.
Funnel plot for publication bias. (A) Placebo. (B) Beta-blocker. (C) Clonidine. (D) Dexmedetomidine. (E) Opioids. (F) Nitroglycerin.
ceo-2020-00584f3.tif
Table 1.
Summary of the studies included in the network meta-analysis
Study Patient (male:female)/age (yr) ENT operation/underlying disease Comparison Outcome measure analyzed Risk of bias of randomized studies
Lee et al. (2013) [35] 66 (34:32)/45.5±12.1 ESS/no cardiovascular disease Dexmedetomidine vs. remifentanil Surgical time Low risk of bias
Adverse effects (hypotension)
Polat et al. (2015) [39] 90 (60:30)/36 (range, 23–53) Nasal surgery (rhinoplasty, septoplasty, ESS)/no cardiovascular disease Dexmedetomidine vs. saline Postoperative pain Low risk of bias
Dexmedetomidine vs. remifentanil Adverse effects (hypotension, PONV)
Kavalci et al. (2013) [28] 60 (34:26)/33.03±12.4 Septoplasty/no cardiovascular disease Dexmedetomidine vs. remifentanil Surgical time Low risk of bias
Gupta et al. (2016) [7] 40 (21:19)/34.13±13.03 ESS/no cardiovascular disease Dexmedetomidine vs. saline Dose of fentanyl Unclear risk of bias
Postoperative pain
Adverse effects (hypotension, PONV)
Ozcan et al. (2012) [29] 50 (25:25)/36.92±12.67 ESS/no cardiovascular disease Dexmedetomidine vs. remifentanil Surgical time High risk of bias
Adverse effects (PONV)
Kumari et al. (2016) [37] 48 (29:17)/36.4±9.7 ESS/no cardiovascular disease Dexmedetomidine vs. saline Operative bleeding Low risk of bias
Kaur et al. (2016) [30] 52 (Sex ratio not reported)/36.96±14.94 ESS/no cardiovascular disease Dexmedetomidine vs. saline Surgical time Unclear risk of bias
Dose of fentanyl
Khurshid et al. (2015) [43] 100 (Sex ratio not reported)/range, 20–60 Nasal surgery (rhinoplasty, septoplasty, ESS)/no cardiovascular disease Dexmedetomidine vs. saline Adverse effects (PONV) Unclear risk of bias
Ayoglu et al. (2008) [6] 40 (22:18)/34.7±10.6 ESS/no cardiovascular disease Dexmedetomidine vs. saline Surgical time Unclear risk of bias
Operative bleeding
Dose of fentanyl
Xu et al. (2016) [31] 60 (40:20)/40.2±11.5 ESS/no cardiovascular disease Dexmedetomidine vs. saline Surgical time Low risk of bias
Adverse effects (PONV)
Gupta et al. (2016) [32] 50 (30:20)/31.2±6.7 ESS/no cardiovascular disease Dexmedetomidine vs. saline Surgical time Unclear risk of bias
Dose of fentanyl
Adverse effects (PONV)
Kim et al. (2013) [33] 100 (72:28)/33 (range, 20–58) Nasal surgery (rhinoplasty, septoplasty, ESS)/no cardiovascular disease Dexmedetomidine vs. saline Surgical time Low risk of bias
Operative bleeding
Postoperative pain
Adverse effects (hypotension, PONV)
Kim et al. (2015) [3] 39 (23:16)/39.2±12.5 ESS/no cardiovascular disease Dexmedetomidine vs. remifentanil Surgical time Low risk of bias
Postoperative pain
Adverse effects (PONV)
Karabayirli et al. (2017) [34] 50 (26:24)/37 (range, 27–46) ESS/no cardiovascular disease Dexmedetomidine vs. remifentanil Surgical time Low risk of bias
Operative bleeding
Surgical field
Adverse effects (PONV)
Cardesin et al. (2015) [9] 47 (29:18)/48.3±13.4 ESS/no cardiovascular disease Clonidine vs. remifentanil Surgical time Low risk of bias
Operative bleeding
Jangra et al. (2016) [12] 20 (10:10)/36.4±9.7 ESS/no cardiovascular disease Beta-blocker (esmolol) vs. saline Surgical time Low risk of bias
Operative bleeding
Tugrul et al. (2016) [14] 52 (28:24)/43.2±8.3 ESS/no cardiovascular disease Clonidine vs. placebo Surgical time Low risk of bias
Operative bleeding
Shams et al. (2013) [1] 40 (Sex ratio not reported)/36.1±8.8 ESS/no cardiovascular disease Beta-blocker (esmolol) vs. dexmedetomidine Surgical time High risk of bias
Operative bleeding
Dose of fentanyl
Jiwanmall et al. (2017) [36] 60 (Sex ratio not reported)/range, 18–65 ESS/no cardiovascular disease Clonidine vs. placebo Surgical time Low risk of bias
Postoperative pain
Adverse effects (hypotension)
Jabalameli et al. (2005) [15] 113 (63:50)/43±12 ESS/no cardiovascular disease Clonidine vs. placebo Surgical time Unclear risk of bias
Operative bleeding
Dose of fentanyl
Mohseni and Ebneshahidi (2011) [17] 84 (50:34)/36±13 ESS/no cardiovascular disease Clonidine vs. placebo Surgical time Low risk of bias
Operative bleeding
Sajedi et al. (2016) [22] 62 (28/34)/36.36±12.35 ESS/no cardiovascular disease Beta-blocker (labetalol) vs. dexmedetomidine Surgical time Unclear risk of bias
Operative bleeding
Dose of fentanyl
Postoperative pain
Adverse effects (hypotension, PONV)
Nair et al. (2004) [25] 80 (50:30)/mean, 43.7 ESS/no cardiovascular disease Beta-blocker (metoprolol) vs. placebo Surgical time Low risk of bias
Operative bleeding
Shen et al. (2011) [26] 40 (31:9)/45.1±3.4 ESS/no cardiovascular disease Beta-blocker (esmolol) vs. placebo Surgical time Low risk of bias
Operative bleeding
Bayram et al. (2015) [27] 60 (Sex ratio not reported)/range, 18–65 ESS/no cardiovascular disease Placebo vs. dexmedetomidine Surgical time Unclear risk of bias
Operative bleeding
Adverse effects (hypotension, PONV)
Praveen et al. (2016) [38] 60 (41:19)/mean, 31.43 ESS/no cardiovascular disease Nitroglycerin vs. dexmedetomidine Operative bleeding Unclear risk of bias
Dose of fentanyl
Das et al. (2016) [13] 60 (48:12)/38.68±9.72 ESS/no cardiovascular disease Beta-blocker (esmolol) vs. dexmedetomidine vs. clonidine Surgical time Low risk of bias
Operative bleeding
Dose of fentanyl
Adverse effects (hypotension, PONV)
Bajwa et al. (2016) [19] 100 (66:34)/36.4±6.1 ESS/no cardiovascular disease Nitroglycerine vs. beta-blocker (esmolol) vs. dexmedetomidine Surgical time Low risk of bias
Dose of fentanyl
Adverse effects (PONV)
Bairy et al. (2017) [10] 59 (26:33)/46±15 ESS/no cardiovascular disease Clonidine vs. opioids (remifentanil) Surgical time Unclear risk of bias
Postoperative pain
Adverse effects (PONV)
Erdivanli et al. (2018) [11] 88 (60:28)/39.3±10.6 ESS/no cardiovascular disease Beta-blocker (metoprolol) vs. opioids (remifentanil) Surgical time Low risk of bias
Postoperative pain
Adverse effects (hypotension, PONV)
Wawrzyniak et al. (2013) [16] 44 (24/:20)/48.6±7.7 ESS/no cardiovascular disease Clonidine vs. placebo Surgical time Unclear risk of bias
Alkan et al. (2019) [18] 60 (43:17)/39 (range, 18–65) ESS/no cardiovascular disease Beta-blocker (esmolol) vs. opioids (remifentanil) vs. nitroglycerin Surgical time High risk of bias
EL-Shmaa et al. (2017) [20] 60 (25:35)/47.6±8.3 ESS/no cardiovascular disease Nitroglycerin vs. beta-blocker (labetalol) Surgical time Low risk of bias
Srivastava et al. (2013) [21] 52 (29:23)/36.27±12.42 ESS/no cardiovascular disease Beta-blocker (esmolol) vs. nitroglycerin Surgical time Low risk of bias
Wawrzyniak et al. (2014) [24] 26 (16:10)/41.4±14.4 ESS/no cardiovascular disease Clonidine vs. placebo Surgical time Low risk of bias
Rahimzadeh et al. (2012) [41] 88 (52:36)/25.9±7 Nasal surgery (rhinoplasty, septoplasty, ESS)/no cardiovascular disease Beta-blocker (esmolol) vs. placebo Adverse effects (hypotension) High risk of bias
Aksu et al. (2009) [40] 40 (25:15)/25.05±9.11 Rhinoplasty/no cardiovascular disease Dexmedetomidine vs. opioids (remifentanil) Adverse effects (hypotension) Unclear risk of bias

Values are presented as mean±standard deviation otherwise indicated.

ESS, endoscopic sinus surgery; PONV, postoperative nausea and vomiting.

Table 2.
Ranked probabilities of the effectiveness of different treatments on the incidence of nausea and vomiting, hypotension, postoperative pain, intraoperative bleeding, intraoperative fentanyl administration, and operative time
Treatment Nausea
 Hypotension
 Pain
 Blood loss
 Intraoperative fentanyl
 Operative time
SUCRA (%) Rank SUCRA (%) Rank SUCRA (%) Rank SUCRA (%) Rank SUCRA (%) Rank SUCRA (%) Rank
Placebo 0.602 2 0.373 4 0.055 5 0 6 0.117 5 0.030 6
Beta-blocker 0.273 6 0.752 1 0.642 2 0.247 5 0.471 3 0.335 5
Clonidine 0.368 5 0.173 5 0.538 3 0.908 1 0.100 1 0.702 2
Dexmedetomidine 0.954 1 0.749 2 0.934 1 0.583 3 - - 0.604 3
Opioids 0.383 4 0.453 3 0.332 4 0.842 2 0.632 2 0.357 4
Nitroglycerin 0.420 3 - - - - 0 6 0.117 5 0.030 6

SUCRA, surface under the cumulative ranking curve.

TOOLS
Similar articles